Acquisition Pending Sponsor buyer

ARCHIMED acquisition of Esperion Therapeutics

US$1.1bn equity value

Announced 1 May 2026 · NASDAQ: ESPR · US$3.16 cash per share · 58% premium

Advisers

Esperion Therapeutics

Target

Financial adviser
Legal adviser
Fairness opinion

ARCHIMED

Acquirer

Financial adviser
Legal adviser
Target
Esperion Therapeutics
Acquirer
ARCHIMED
Target based in
United States
Buyer based in
France
Sector
Pharma
Tags
Pharma, Cardiovascular

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.